Resolve Therapeutics Announces Publication of Lupus Clinical Trial Results
- Equities close slightly lower as focus shifts to data
- Zoom Video Communications guidance tops estimates following Q4 results beat
- Corporate profitability set to weaken - JPMorgan
- Global equities index sluggish with inflation in focus, oil climbs
- Nancy Pelosi buys Palo Alto Networks (PANW) call options, shares pop
The publication entitled "Evaluation of RNase therapy in systemic lupus erythematosus: a randomized phase 2a clinical trial of RSLV-132" describes a proof-of-concept study in SLE patients with moderate-severe cutaneous disease activity. The findings suggest that patients with Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2k) scores above nine respond preferentially to digestion of extracellular RNA as compared to patients with lower SLEDAI-2k scores less than nine.
"We would like to express our deepest gratitude to the patients that participated in the study" commented Dr.
RSLV-132 is a non-immunosuppressive, biologic drug comprised of catalytically active human RNase1 fused to the Fc region of human IgG1. It is designed to remain in serum circulation and digest extracellular pathogenic RNA in patients with autoimmune diseases. RNA is the primary trigger of interferon production and drives chronic inflammation in autoimmune diseases such as SLE and Sjogren's, therefore removing it from circulation may decrease inflammation and improve the symptoms associated with these autoimmune diseases.
About Resolve Therapeutics
Resolve is a private biotech company pioneering a completely new approach to autoimmune disease. The company is leveraging the extensive body of scientific discoveries that demonstrate the central role of pathogenic RNA molecules in autoimmune disease. Resolve is actively developing RSLV-132 in mid-stage clinical development programs icluding SLE, Sjogren's syndrome, and post-acute sequelae of SARS-CoV-2 infection (PASC). For more information please visit: https://resolvetherapeutics.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/resolve-therapeutics-announces-publication-of-lupus-clinical-trial-results-302059570.html
SOURCE Resolve Therapeutics, LLC
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Global Times: 'Xiamen solution' exemplifies harmonious coexistence between man and nature, contributes to global marine governance
- Form 8.5 (EPT/RI) - FireAngel Safety Technology Group Plc
- NEXSTIM PLC’S FINANCIAL STATEMENTS BULLETIN 2023
Create E-mail Alert Related CategoriesPRNewswire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!